Company: BLCO
Filing Date: 2025-10-29
Form Type: 10-Q
Source: 0001860742-25-000023
Chunk: 122

Company: Bausch & Lomb Corp
Filing Date: 2025-10-29
Form: 10-Q
Item: Item 2
Chunk 122
---
 titled non-GAAP financial measures and ratios used by other companies.

41

The following table presents a reconciliation of Revenues to constant currency revenues (non-GAAP) and the period-over-period changes in constant currency revenue (non-GAAP) for the three months ended September 30, 2025 and 2024. Three Months Ended September 30, 2025Three Months Ended September 30, 2024Change inConstant Currency Revenue(Non-GAAP)RevenueasReportedChanges in Exchange RatesConstant Currency Revenue(Non-GAAP)RevenueasReported(in millions)AmountPct.Vision Care$736 $(11)$725 $684 $41 6 %Pharmaceuticals330 (2)328 306 22 7 %Surgical215 (6)209 206 3 1 %Total$1,281 $(19)$1,262 $1,196 $66 6 %Vision Care Segment RevenueThe Vision Care segment revenue was $736 million and $684 million for the three months ended September 30, 2025 and 2024, respectively, an increase of $52 million, or 8%. The increase was primarily driven by sales from our dry eye portfolio and eye vitamins portfolio within our consumer eye care business and the performance of SiHy Daily lenses and Biotrue® within our contact lens business. This increase included: (i) an increase in volumes of $30 million, (ii) an increase in net pricing of $14 million and (iii) the favorable impact of foreign currencies of $11 million, partially offset by the impact of divestitures and discontinuations of $3 million.Pharmaceuticals Segment RevenueThe Pharmaceuticals segment revenue was $330 million and $306 million for the three months ended September 30, 2025 and 2024, respectively, an increase of $24 million, or 8%. The increase was primarily driven by: (i) the increased net sales in our branded pharmaceuticals business, driven by MIEBO® and its continued positive momentum since launching, and (ii) increased sales in our international pharmaceuticals business, partially offset by declines in the U.S. generics business. This increase included: (i) an increase in volumes of $44 million and (ii) the favorable impact of foreign currencies of $2 million, partially offset by a decrease in net realized pricing of $21 million.Surgical Segment RevenueThe Surgical segment revenue was $215 million and $206